Patents by Inventor Paul Parren

Paul Parren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210324096
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: December 1, 2020
    Publication date: October 21, 2021
    Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20210317225
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 14, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • Antibodies
    Patent number: 11130819
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: September 28, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20210292414
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: December 11, 2020
    Publication date: September 23, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210277133
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 9, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • METHOD FOR PRODUCING A CONTROLLED MIXTURE OF TWO OR MORE DIFFERENT ANTIBODIES
    Publication number: 20210269509
    Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.
    Type: Application
    Filed: June 24, 2019
    Publication date: September 2, 2021
    Inventors: Richard HIBBERT, Rob DE JONG, Aran Frank LABRIJN, Arnout GERRITSEN, Janine SCHUURMAN, Paul PARREN
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210269541
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 2, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20210269524
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 13, 2020
    Publication date: September 2, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20210253725
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Monoclonal antibodies against HER2
    Patent number: 11091553
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 17, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Methods of producing multispecific antibodies against CD40 and CD137
    Patent number: 11091557
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 17, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11084882
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 10, 2021
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • ANTIBODIES
    Publication number: 20210230296
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • DIMERIC PROTEIN WITH TRIPLE MUTATIONS
    Publication number: 20210230301
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 29, 2021
    Inventors: Rob N. DE JONG, Frank BEURSKENS, Paul PARREN, Aran Frank LABRIJN, Janine SCHUURMAN, Arjen VLUG, Sandra VERPLOEGEN
  • Monoclonal antibodies against HER2
    Patent number: 11046771
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 29, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
    Patent number: 11034772
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: June 15, 2021
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20210171657
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 21, 2020
    Publication date: June 10, 2021
    Applicants: GENMAB A/S, GENMAB A/S
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, D.M.Sc., Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210163616
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20210163619
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: July 6, 2020
    Publication date: June 3, 2021
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Aran Frank LABRIJN, Janine SCHUURMAN
  • ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION
    Publication number: 20210155699
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 27, 2021
    Applicant: Genmab A/S
    Inventors: Aran Frank LABRIJN, Stefan LOVERIX, Paul PARREN, Jan VAN DE WINKEL, Janine SCHUURMAN, Ignace LASTERS